Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 14/20 | 0.49 |
| ▸ | LYN | P07948 | 11/20 | 0.49 |
| ▸ | SRC | P12931 | 10/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193568 | 0.87 | RIPK2 (0.43) | RIPK2ACVR1NOD2BTKLYN | |
| SCHEMBL16193581 | 0.85 | RIPK2 (0.45) | RIPK2ACVR1NOD2BTKLYN | |
| SCHEMBL4710907 | 0.83 | FGFR1 (0.49) | RIPK2ACVR1NOD2BTKLYN | |
| SCHEMBL16194280 | 0.83 | EGFR (0.41) | RIPK2ACVR1NOD2BTKLYN | |
| SCHEMBL4563490 | 0.82 | GAK (0.39) | RIPK2ACVR1NOD2BTKLYN | |
| SCHEMBL5266722 | 0.81 | FGFR1 (0.35) | BTKLYNSRCEGFRFGFR1 | |
| SCHEMBL1982506 | 0.80 | ALDH1A1 (0.42) | SRCEGFRFGFR1 | |
| SCHEMBL15771218 | 0.80 | EGFR (0.45) | EGFRFGFR1 | |
| SCHEMBL1680882 | 0.79 | BTK (0.43) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL660415 | 0.79 | BTK (0.51) | RIPK2ACVR1NOD2BTKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | RIPK2 1265/4885ACVR1 4869/4885NOD2 4195/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | RIPK2 1841/4885ACVR1 4507/4885NOD2 4275/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | RIPK2 915/4885ACVR1 4814/4885NOD2 4592/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | RIPK2 884/4885ACVR1 4852/4885NOD2 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.